These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

33 related articles for article (PubMed ID: 18533259)

  • 1. Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia.
    Kim Y; Go TH; Jang J; Lee JB; Lim ST; Shim KY; Lee JI; Kong JH
    Korean J Intern Med; 2021 Nov; 36(6):1450-1458. PubMed ID: 34742178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan.
    Tsai YF; Huang WC; Cho SF; Hsiao HH; Liu YC; Lin SF; Liu TC; Chang CS
    Medicine (Baltimore); 2018 Jun; 97(26):e11322. PubMed ID: 29953021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.
    Noens L; Hensen M; Kucmin-Bemelmans I; Lofgren C; Gilloteau I; Vrijens B
    Haematologica; 2014 Mar; 99(3):437-47. PubMed ID: 24598855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients.
    Moon JH; Sohn SK; Kim SN; Park SY; Yoon SS; Kim IH; Kim HJ; Kim YK; Min YH; Cheong JW; Kim JS; Jung CW; Kim DH
    Med Oncol; 2012 Jun; 29(2):1179-85. PubMed ID: 21472487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era.
    Muramatsu H; Takahashi Y; Sakaguchi H; Shimada A; Nishio N; Hama A; Doisaki S; Yagasaki H; Matsumoto K; Kato K; Kojima S
    Int J Hematol; 2011 Feb; 93(2):186-191. PubMed ID: 21234820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism.
    Breccia M; Alimena G
    Leuk Res; 2009 Jul; 33(7):871-5. PubMed ID: 19307018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chronic myeloid leukemia and imatinib mesylate therapy].
    Chrobák L
    Vnitr Lek; 2004 Jan; 50(1):10-2. PubMed ID: 15015223
    [No Abstract]   [Full Text] [Related]  

  • 8. Listeria monocytogenes meningitis following imatinib mesylate-induced monocytopenia in a patient with chronic myeloid leukemia.
    Ferrand H; Tamburini J; Mouly S; Bouscary D; Bergmann JF
    Clin Infect Dis; 2005 Dec; 41(11):1684-5. PubMed ID: 16267747
    [No Abstract]   [Full Text] [Related]  

  • 9. Fluorescence in situ hybridization analysis of minimal residual disease and the relevance of the der(9) deletion in imatinib-treated patients with chronic myeloid leukemia.
    Calabrese G; Fantasia D; Di Gianfilippo R; Stuppia L; Di Lorenzo R; Palka G
    Haematologica; 2006 Jul; 91(7):994-5. PubMed ID: 16818290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic effects of imatinib on chronic myeloid leukemia in different phases and the factors affecting the effects].
    Zou WY; Xu DR; Su C; Li J; Luo SK
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1660-2. PubMed ID: 18819894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.
    Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T
    Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834
    [No Abstract]   [Full Text] [Related]  

  • 12. Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase.
    Kiguchi T; Tauchi T; Ito Y; Miyazawa K; Kimura Y; Ohyashiki K
    Leuk Res; 2009 Mar; 33(3):506-8. PubMed ID: 18533259
    [No Abstract]   [Full Text] [Related]  

  • 13. [Initial therapy of imatinib mesylate for extramedullary T lymphoblastic crisis of chronic myeloid leukemia: a case report and review of the literature].
    He HS; Su GP; Chen BB
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):477-8. PubMed ID: 22213870
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.